BioSpace News Archive

IRLAB to Present the Company at ProHearings on September 29, 2022

IRLAB Therapeutics AB announced that Richard Godfrey, CEO of IRLAB, will present the company at ProHearings on Thursday, September 29, 2022, at 10:20 am CEST.

September 28, 2022
·
1 min read
Press Release: Availability of the Q3 2022 Memorandum for modelling purposes

Sanofi announced that its Q3 2022 Memorandum for modelling purposes is available on the “Investors” page of the company’s website:

September 28, 2022
·
4 min read
Cleara Biotech Raises $2.5 Million in Seed Financing to Advance FOXO4-Therapeutics Pipeline for Treating Cancer and Chronic Diseases

CLEARA Biotech B.V. announced that it closed a $2.5 million seed financing round earlier in the year, led by Apollo Health Ventures, with participation from Curie Capital B.V., ROM Utrecht Region and Longevity Tech Fund.

September 28, 2022
·
4 min read
Pharm Country

Olympus Launches THUNDERBEAT Energy Device for Open Surgery

Olympus Corporation announced the release of the THUNDERBEAT™ Open Fine Jaw Type X surgical energy devices for open surgery.

September 28, 2022
·
3 min read
Angle PLC announces Study using Parsortix in head and neck cancer

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that the University of Birmingham has published the results of a study undertaken in head and neck squamous cell carcinoma which characterised the epithelial-mesenchymal transition status of circulating tumour cells.

September 28, 2022
·
9 min read
Photocure Announces the Commercial Availability of Karl Storz’s New Blue Light System in the U.S.

Photocure ASA, the Bladder Cancer Company, announces the commercial availability of Karl Storz’s New Blue Light equipment powered by Saphira™ in the U.S.

September 28, 2022
·
5 min read
AcuCort reports positive results from the company’s questionnaire study about allergy treatments

AcuCort AB reports positive results from the company’s questionnaire study on how allergy patients value their treatment.

September 28, 2022
·
3 min read
Policy

European Medicines Agency Accepts Moderna’s Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine

Moderna, Inc. announced that the European Medicines Agency has accepted a variation for the evaluation of a 50 µg booster dose of the Omicron-containing bivalent COVID booster candidate, mRNA-1273.222 in adults 12 years and older.

September 28, 2022
·
4 min read
Drug Development

PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Inc. announced results from its completed Phase 1 healthy normal volunteer trial of PGN-EDO51, the company’s lead product candidate for the treatment of DMD patients whose mutations are amenable to an exon 51 skipping approach.

September 28, 2022
·
11 min read
BioMidwest

Pediatric and Autonomic Dysfunction Long COVID Symptoms Guidance Statements Released by the American Academy of Physical Medicine and Rehabilitation

The American Academy of Physical Medicine and Rehabilitation announced new guidance for diagnosing and treating pediatric patients with Long COVID symptoms and patients with autonomic dysfunction symptoms of Long COVID.

September 28, 2022
·
4 min read